company background image
0KCS logo

OPKO Health LSE:0KCS Stock Report

Last Price

US$1.49

Market Cap

US$1.0b

7D

-0.6%

1Y

15.5%

Updated

11 Oct, 2024

Data

Company Financials +

0KCS Stock Overview

A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally.

0KCS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OPKO Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OPKO Health
Historical stock prices
Current Share PriceUS$1.49
52 Week HighUS$1.74
52 Week LowUS$0.85
Beta1.63
11 Month Change-3.80%
3 Month Change8.05%
1 Year Change15.53%
33 Year Change-60.36%
5 Year Changen/a
Change since IPO-69.46%

Recent News & Updates

Recent updates

Shareholder Returns

0KCSGB HealthcareGB Market
7D-0.6%-2.0%-0.6%
1Y15.5%-14.4%6.6%

Return vs Industry: 0KCS exceeded the UK Healthcare industry which returned -14.4% over the past year.

Return vs Market: 0KCS exceeded the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0KCS's price volatile compared to industry and market?
0KCS volatility
0KCS Average Weekly Movement6.8%
Healthcare Industry Average Movement7.2%
Market Average Movement4.6%
10% most volatile stocks in GB Market9.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0KCS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0KCS's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20073,930Phil Frostwww.opko.com

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.

OPKO Health, Inc. Fundamentals Summary

How do OPKO Health's earnings and revenue compare to its market cap?
0KCS fundamental statistics
Market capUS$1.02b
Earnings (TTM)-US$243.10m
Revenue (TTM)US$716.37m

1.4x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0KCS income statement (TTM)
RevenueUS$716.37m
Cost of RevenueUS$619.86m
Gross ProfitUS$96.51m
Other ExpensesUS$339.61m
Earnings-US$243.10m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin13.47%
Net Profit Margin-33.93%
Debt/Equity Ratio14.5%

How did 0KCS perform over the long term?

See historical performance and comparison